Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RTI Surgical, Inc. (RTIX) Announces First Human Implantation Of Map3 Cellular Allogeneic Bone Graft

|Includes: RTI Surgical, Inc. (RTIX)

Global surgical implant company RTI Surgical announced that the first human implantation of the company's map3 Cellular Allogeneic Bone Graft implant was completed last week.

This first implantation was performed during a spinal surgery in New York by Dr. Franco E. Vigna, M.D., M.P.H., who is a board certified orthopedic surgeon with Spine Surgery of Buffalo Niagara and a fellow with the American Academy of Orthopaedic Surgeons. Dr. Vigna used the implant's chips allograft configuration, which is one of two configurations that will be available once the implant is launched.

Vigna, who was honored in 2009 as one of the top American orthopedists in spinal care by the Consumers' Research Council of America, said he is excited to have map3 available as an option for his patients, due to the implant's specific osteogenic and angiogenic properties.

"The future of spine surgery is biologics," Vigna said. "We can place the best metal implants, but if the bony fusion does not take place those implants will loosen and the fusion will fail. Having top-quality natural biologics along with excellent metal implants gives physicians and patients the best of both worlds."

A natural and safe alternative to autograft, map3 cellular allogeneic bone graft provides a streamlined approached to bone grafting and, in a single allograft, supplies the three elements necessary for bone repair: osteogenesis, osteoinduction, and osteoconduction. Map3 incorporates multipotent adult progenitor cell-based (MAPC-based) technology with stem cells that are isolated from the same donor as the other bone material. This technology, which is licensed from Athersys for this specific orthopedic application, represents a distinct type of stem cell with recognized angiogenic and immune-modulatory properties. Once it has been launched, map3 will be available in multiple configurations and sizes and will provide bone grafting options for a variety of bone repair, reconstruction, and fusion procedures.

RTI anticipates map3's market release to take place later this year. Surgeons can learn more about the implant and RTI's other offerings at the North American Spine Society's (NASS) Annual Meeting, which will take place Oct. 9-12 in New Orleans. RTI's exhibit will be located at booth #621.

For more information, visit rtix.com

Please see disclaimer on the MissionIR website

www.missionir.com/disclaimer.html